Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Maridebart Cafraglutide

Stage Phase 3Stale

Sponsor Amgen

Route subcutaneous

Modality peptide-antibody conjugate

Class GLP-1 conjugate

Mechanism glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism

Target GLP-1 receptor and GIP receptor (TEC-0013)

Sources

publication, as of 2025-06-23Stale

https://pubmed.ncbi.nlm.nih.gov/40549887/

Maridebart cafraglutide is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism. It was given subcutaneously. In the obesity cohort, the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% to -16.2% with maridebart cafraglutide, as compared with -2.5% with placebo.

N Engl J Med 2025;393:843-857, PMID 40549887, abstract

registry, as of 2026-01-20Stale

https://clinicaltrials.gov/study/NCT05669599

Protocol section, NCT05669599, last update posted 2026-01-20

registry, as of 2026-09-17Stale

https://clinicaltrials.gov/study/NCT06858839

Protocol section, NCT06858839 MARITIME-1, last update posted 2026-09-17

registry, as of 2026-10-29Stale

https://clinicaltrials.gov/study/NCT07037433

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 12800. Conditions Atherosclerotic Cardiovascular Disease; Overweight; Obesity. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

ClinicalTrials.gov NCT07037433 protocol and results modules

registry, as of 2026-10-29Stale

https://clinicaltrials.gov/study/NCT07037459

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 5056. Conditions Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with pres

ClinicalTrials.gov NCT07037459 protocol and results modules

registry, as of 2026-10-05Stale

https://clinicaltrials.gov/study/NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 3200. Conditions Obesity; Overweight. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

ClinicalTrials.gov NCT07684235 protocol and results modules

registry, as of 2025-12-31Stale

https://clinicaltrials.gov/study/NCT06858878

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 1105. Conditions Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight. The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

ClinicalTrials.gov NCT06858878 protocol and results modules

registry, as of 2026-10-05Stale

https://clinicaltrials.gov/study/NCT07684144

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 950. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

ClinicalTrials.gov NCT07684144 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07575399

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH). Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 300. Conditions Obesity or Overweight. Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

ClinicalTrials.gov NCT07575399 protocol and results modules

registry, as of 2025-12-17Stale

https://clinicaltrials.gov/study/NCT06987695

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 279. Conditions Obesity Disease. The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.

ClinicalTrials.gov NCT06987695 protocol and results modules

registry, as of 2026-10-06Stale

https://clinicaltrials.gov/study/NCT07225686

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 250. Conditions Obesity; Obstructive Sleep Apnea. This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or

ClinicalTrials.gov NCT07225686 protocol and results modules

registry, as of 2026-09-29Stale

https://clinicaltrials.gov/study/NCT07226765

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 250. Conditions Obstructive Sleep Apnea. This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.

ClinicalTrials.gov NCT07226765 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07871409

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 230. Conditions Obesity; Overweight. The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

ClinicalTrials.gov NCT07871409 protocol and results modules

registry, as of 2026-09-11Stale

https://clinicaltrials.gov/study/NCT06660173

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Amgen. Enrollment 409. Conditions Type 2 Diabetes Mellitus (T2DM). The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

ClinicalTrials.gov NCT06660173 protocol and results modules

registry, as of 2026-09-28Stale

https://clinicaltrials.gov/study/NCT07441252

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Amgen. Enrollment 180. Conditions Overweight or Obesity and Elevated Liver Fat. The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with r

ClinicalTrials.gov NCT07441252 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07921316

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Amgen. Enrollment 356. Conditions Obesity; Overweight. The main objective of this study is to compare the pharmacokinetics of maridebart cafraglutide administered as a single dose using two different subcutaneous (SC) presentations in participants with overweight or obesity after they have received escalating doses of the study drug.

ClinicalTrials.gov NCT07921316 protocol and results modules

registry, as of 2026-08-07Stale

https://clinicaltrials.gov/study/NCT07313761

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Amgen. Enrollment 349. Conditions Overweight and Obesity. The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

ClinicalTrials.gov NCT07313761 protocol and results modules

registry, as of 2026-06-17Stale

https://clinicaltrials.gov/study/NCT07226778

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Amgen. Enrollment 348. Conditions Overweight; Obesity. The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

ClinicalTrials.gov NCT07226778 protocol and results modules

Studies

NCT05669599

Registry NCT05669599

Phase Phase 2

Status Completed

Enrollment 592

Start 2023-01-18

Primary completion 2024-10-08

Study completion 2025-12-16

Cohort A: Maridebart Cafraglutide

Regimen subcutaneous

Weeks 52

Population participants with obesity

Estimand ITT

percent change in body weight, week 52

Cohort A: Placebo

Cohort B: Maridebart Cafraglutide

Cohort B: Placebo

MARITIME-1

Registry NCT06858839

Phase Phase 3

Status Active, not recruiting

Enrollment 3853

Start 2025-03-12

Primary completion 2027-01-21

Catalyst Primary completion. 2027-01-21Stale

Maridebart Cafraglutide High Dose

Maridebart Cafraglutide Medium Dose

Maridebart Cafraglutide Low Dose

Placebo

MARITIME-CV

Registry NCT07037433

Phase Phase 3

Status Active, not recruiting

Enrollment 12800

Start 2025-07-25

Primary completion 2028-06-30

Study completion 2030-09-29

Catalyst Primary completion. 2028-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Comparator placebo

Population Atherosclerotic Cardiovascular Disease; Overweight; Obesity

Placebo

Population Atherosclerotic Cardiovascular Disease; Overweight; Obesity

MARITIME-HF

Registry NCT07037459

Phase Phase 3

Status Recruiting

Enrollment 5056

Start 2025-06-25

Primary completion 2028-06-30

Study completion 2030-09-29

Catalyst Primary completion. 2028-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Comparator placebo

Population Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity

Placebo

Population Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Registry NCT07684235

Phase Phase 3

Status Recruiting

Enrollment 3200

Start 2026-07-23

Primary completion 2027-12-26

Study completion 2028-03-19

Catalyst Primary completion. 2027-12-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide Low Dose Q4W

Comparator placebo

Population Obesity; Overweight

Maridebart Cafraglutide Medium Dose Q4W

Comparator placebo

Population Obesity; Overweight

Maridebart Cafraglutide Medium Dose Q8W

Comparator placebo

Population Obesity; Overweight

Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)

Population Obesity; Overweight

Maridebart Cafraglutide High Dose Q4W

Comparator placebo

Population Obesity; Overweight

Maridebart Cafraglutide High Dose Q8W

Comparator placebo

Population Obesity; Overweight

Maridebart Cafraglutide High Dose Q12W

Comparator placebo

Population Obesity; Overweight

Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)

Population Obesity; Overweight

Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)

Population Obesity; Overweight

Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)

Comparator placebo

Population Obesity; Overweight

MARITIME-2

Registry NCT06858878

Phase Phase 3

Status Active, not recruiting

Enrollment 1105

Start 2025-03-17

Primary completion 2027-01-21

Study completion 2027-04-16

Catalyst Primary completion. 2027-01-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide High Dose

Comparator placebo

Population Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Maridebart Cafraglutide Medium Dose

Comparator placebo

Population Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Maridebart Cafraglutide Low Dose

Comparator placebo

Population Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Placebo

Population Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Registry NCT07684144

Phase Phase 3

Status Recruiting

Enrollment 950

Start 2026-07-29

Primary completion 2027-12-26

Study completion 2028-03-19

Catalyst Primary completion. 2027-12-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide Low Dose Q4W

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide Medium Dose Q4W

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide Medium dose Q8W

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide High Dose Q4W

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide High Dose Q8W

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SW

Registry NCT07575399

Phase Phase 3

Status Recruiting

Enrollment 300

Start 2026-05-11

Primary completion 2028-01-03

Study completion 2028-02-28

Catalyst Primary completion. 2028-01-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

MariTide Arm 1

Population Obesity or Overweight

MariTide Arm 2

Population Obesity or Overweight

MARITIME-3-J

Registry NCT06987695

Phase Phase 3

Status Active, not recruiting

Enrollment 279

Start 2025-06-13

Primary completion 2027-04-27

Study completion 2027-07-21

Catalyst Primary completion. 2027-04-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide High Dose

Comparator placebo

Population Obesity Disease

Maridebart Cafraglutide Medium Dose

Comparator placebo

Population Obesity Disease

Maridebart Cafraglutide Low Dose

Comparator placebo

Population Obesity Disease

Placebo

Population Obesity Disease

MARITIME-OSA-1

Registry NCT07225686

Phase Phase 3

Status Active, not recruiting

Enrollment 250

Start 2025-12-19

Primary completion 2027-08-20

Study completion 2028-07-21

Catalyst Primary completion. 2027-08-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Comparator placebo

Population Obesity; Obstructive Sleep Apnea

Placebo

Population Obesity; Obstructive Sleep Apnea

MARITIME-OSA-2

Registry NCT07226765

Phase Phase 3

Status Active, not recruiting

Enrollment 250

Start 2025-11-25

Primary completion 2027-08-30

Study completion 2028-09-13

Catalyst Primary completion. 2027-08-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Comparator placebo

Population Obstructive Sleep Apnea

Placebo

Population Obstructive Sleep Apnea

MARITIME-PEN

Registry NCT07871409

Phase Phase 3

Status Not yet recruiting

Enrollment 230

Start 2026-10-28

Primary completion 2027-06-16

Study completion 2027-09-08

Catalyst Primary completion. 2027-06-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart cafraglutide

Population Obesity; Overweight

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Registry NCT06660173

Phase Phase 2

Status Active, not recruiting

Enrollment 409

Start 2024-11-07

Primary completion 2025-10-06

Study completion 2026-11-10

Catalyst Primary completion. 2025-10-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Comparator placebo

Population Type 2 Diabetes Mellitus (T2DM)

Placebo

Population Type 2 Diabetes Mellitus (T2DM)

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Registry NCT07441252

Phase Phase 2

Status Active, not recruiting

Enrollment 180

Start 2026-03-05

Primary completion 2027-08-25

Study completion 2027-11-17

Catalyst Primary completion. 2027-08-25. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide

Regimen every 4 weeks

Weeks 4

Comparator placebo

Population Overweight or Obesity and Elevated Liver Fat

Placebo

Regimen every 4 weeks

Weeks 4

Population Overweight or Obesity and Elevated Liver Fat

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses

Registry NCT07921316

Phase Phase 1

Status Not yet recruiting

Enrollment 356

Start 2026-11-09

Primary completion 2027-07-26

Study completion 2027-07-26

Catalyst Primary completion. 2027-07-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Maridebart Cafraglutide: SC Presentation 1

Population Obesity; Overweight

Maridebart Cafraglutide: SC Presentation 2

Population Obesity; Overweight

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Registry NCT07313761

Phase Phase 1

Status Completed

Enrollment 349

Start 2025-12-15

Primary completion 2026-07-02

Study completion 2026-07-02

Catalyst Primary completion. 2026-07-02. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide SC Presentation 1

Population Overweight and Obesity

Maridebart Cafraglutide SC Presentation 2

Population Overweight and Obesity

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Registry NCT07226778

Phase Phase 1

Status Completed

Enrollment 348

Start 2025-10-10

Primary completion 2026-05-28

Study completion 2026-05-28

Catalyst Primary completion. 2026-05-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Maridebart Cafraglutide SC Presentation 1

Population Overweight; Obesity

Maridebart Cafraglutide SC Presentation 2

Population Overweight; Obesity